About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The goal of the Shock, Organic Dysfunction and Resuscitation Research Group (SODIR) is comprehensive, innovative research into the areas of shock, acute respiratory failure, acute kidney failure, organic dysfunction, resuscitation and critical patient monitoring. In addition, the research group has a special interest in applying artificial intelligence as an instrument to find innovative solutions for critical patients.
The research line in ECMO, led by Dr. J. Riera, aims at clinical research in ECMO and the development of advanced simulation models in ECMO with the technology industry, such as the Hybrids VITA system, already marketed, which allows the realization of ECMO in a realistic simulation environment.
IP: Jordi Riera del Brío
The research line in critically ill patient monitoring, led by Dr.J.C.Ruiz, has as objectives the research in the application of echocardiography and other non-invasive or minimally invasive monitoring systems in the study of the pathophysiological mechanisms of the hemodynamic and cardiac dysfunction of the critical patient, and the study of microcirculation and its involvement in the pathophysiology of severe sepsis with multiorgan dysfunction.
IP: Juan Carlos Ruiz Rodriguez
SODIR has created the Clinical Research Unit for to participate in the clinical trials promoted by the industry. This Unit centralizes all the clinical trials that are developed in the Group and allows a professional management of clinical trials, being a very positive and highly valued imput by the pharma companys. The Unit also give support to competitive research projects. Actually we are working in 14 clinical trials focused mainly on the field of sepsis and infectious diseases. The Unit is formed by nursing and doctors exclusively dedicated to clinical research (24 hours, 7 days/week).
IP: Ricard Ferrer Roca
The research line acute renal failure kidney focuses in extracorporeal replacement therapies and acute kidney injury.
Mainly attention has been focused on continuous renal replacement therapy (CRRT), to which absorptive therapies and hepatic replacement therapies have been linked. In relation to CRRT we have recently participated in the REGISFRA multicentric study, whose objective was to draw a map of CRRT in Catalonia. In addition, our attention is focused on projects of therapy optimization concerning type and dosage as well as in biomarkers that can early predict the requirement of CRRT in our patients.
In relation to acute kidney injury (AKI), the projects are based on the early recognition of patients at risk for AKI and on the prophylactic measures necessary to prevent these patients from finally developing an AKI.
IP: Marcos Pérez Carrasco
IP: Luis silvestre Chiscano Camon Collaborators: Ricard Ferrer Roca, Juan Carlos Ruiz Rodriguez, Vicente J. Ribas Ripoll Funding agency: Fundació Institut de Recerca HUVH Funding: 13500 Reference: VHIR-FIT-2025-001 Duration: 01/07/2025 - 30/06/2026
IP: Montserrat Aran Esteve Collaborators: Rocio Amalia Tabernero Gallego, Elisabet Gallart Vive, Rosa Maria Gracia Gozalo, Montse Rodriguez Gomez, Xavier Nuvials Casals, Nuria Vidal Tarrasón, Isidro Alcalà Jimenez, Adoración Nieto Ruiz, Laia Rafel Perez Funding agency: Col·legi Oficial d'Infermers/es de Barcelona Funding: 7502 Reference: PR-724/2024 Duration: 01/01/2025 - 31/12/2027
IP: Ricard Ferrer Roca Collaborators: Andres Francisco Pacheco Reyes, Alba Gómez Garrido, Francisco Javier Ramos Gómez, Gonzalo Ballesteros Reviriego Funding agency: Ministerio de Ciencia e Innovación-MICINN Funding: 221996 Reference: CPP2023-010467 Duration: 01/05/2024 - 30/04/2027
IP: Ricard Ferrer Roca Collaborators: - Funding agency: EUROPEAN COMMISSION Funding: 97370 Reference: INDICATE_HE_DIGI-2024 Duration: 01/12/2024 - 31/03/2028
PhD student: Jaume Oriol Baldira Martinez D Iruj Director/s: Ricard Ferrer Roca, Juan Carlos Ruiz Rodriguez University: Year: 2024
PhD student: Eduard Argudo Serra Director/s: Jordi Riera del Brío, Ricard Ferrer Roca University: Universitat Autònoma de Barcelona Year: 2024
PhD student: Luis silvestre Chiscano Camon Director/s: Ricard Ferrer Roca, Juan Carlos Ruiz Rodriguez University: Universitat Autònoma de Barcelona Year: 2024
PhD student: Jesús Caballero López Director/s: Ricard Ferrer Roca, Juan Carlos Ruiz Rodriguez University: Universitat Autònoma de Barcelona Year: 2023
PhD student: Alexandra Cortina Gutierrez, Alexandra Cortina Gutierrez Director/s: Alberto Sandiumenge Camps, Xavier Nuvials Casals University: Universidad Autònoma de Barcelona Year: 2022
PhD student: Xavier Nuvials Casals, Xavier Nuvials Casals Director/s: Mercedes Palomar Martínez University: Universidad Autònoma de Barcelona Year: 2016
PhD student: Jordi Riera del Brío Director/s: Teresa Pont Castellana, Jordi Rello Condomines University: Universidad Autònoma de Barcelona Year: 2015
PhD student: Juan Carlos Ruiz Rodriguez Director/s: Miguel Vilardell Tarres, Joaquín Serra Vich, Miguel Vilardell Tarres University: Universidad Autònoma de Barcelona Year: 2015
PhD student: Marcos Pérez Carrasco, Marcos Pérez Carrasco Director/s: Joan Ramon Masclans Enviz, Ferran Morell Brotad, Ferran Morell Brotad University: Universidad Autònoma de Barcelona Year: 2015
PhD student: Oriol Roca Gas Director/s: Joan Ramon Masclans Enviz, Fco. Javier Muñoz Gall University: Universidad Autònoma de Barcelona Year: 2010
The study will be conducted in the Intensive Care Medicine Service of the Vall d’Hebron University Hospital and will validate the prognostic value of the NLRP3 biomarker.
SOFA-2 is being updated after thirty years to incorporate advances in diagnosis, monitoring and life support.
On European Antibiotic Awareness Day, we highlight the importance of using these medications responsibly and finding innovative solutions to combat this issue.
